- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05901441
Effect of Epidural Hydromorphone Combined With Ropivacaine in Labor Analgesia
The purpose of this study is to compare the effects of three different doses of hydromorphone combined with ropivacaine and sufentanil combined with ropivacaine in epidural labor analgesia through prospective clinical trials, so as to explore whether hydromorphone combined with ropivacaine has advantages in epidural labor analgesia, and find out the optimal dose of hydromorphone.
Participants will be randomly allocated to four groups: H1 group,H2 group,H3 group and SF group.For those in H1 group: they will be administered with15 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in H3 group: they will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in SF group: they will be administered with 40 ug/ml sufentanil and 0.08% ropivacaine for epidural labor analgesia.
The goal of this clinical trial is to provide a new treatment option for pregnant women in epidural labor analgesia, and to provide a basis for hydromorphone combined with ropivacaine in epidural labor analgesia.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430000
- Maternal and Child Health Hospital of Hubei Province
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
no contraindication of intraspinal anesthesia the American Society of Anesthesiologists(ASA) physical status ranked Ⅰ-Ⅱ competent to provide informed consent
Exclusion Criteria:
poor respiratory functions severe cardiovascular diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: H1 group
H1 group will be administered with15 ug/ml hydromorphone and 0.08% ropivacaine
|
For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone
0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
|
Experimental: H2 group
H2 group will be administered with17.5 ug/ml hydromorphone and 0.08% ropivacaine
|
For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone
0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
|
Experimental: H3 group
H3 group will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine
|
For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone
0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
|
Active Comparator: SF group
SF group will be administered with 40 ug/ml sufentanil and 0.08% ropivacaine
|
0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
For those in SF group: they will be administered with 40 ug/ml sufentanil
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Analogue Scale(VAS)
Time Frame: 30 minutes-1 hour
|
VAS will be monitored and recorded at 6 time points, including the time of entering the operating room(Time 0), when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), when the first dose is given for 30 minutes(Time 3), 30 minutes after delivery (Time 4), and 60 minutes after delivery (Time 5).
The VAS consists of a 10 cm line,with two end points representing 0 (no pain) and 10 (pain as bad as it could possibly be).
|
30 minutes-1 hour
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heart rate(HR)
Time Frame: 30 minutes-1.5 hours
|
HR will be monitored and recorded at 5 time points, including the time of entering the operating room(Time 0),when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), 30 minutes after delivery (Time 3), and 60 minutes after delivery (Time 4).
|
30 minutes-1.5 hours
|
Mean arterial pressure(MAP)
Time Frame: 30 minutes-1.5 hours
|
MAP will be monitored and recorded at 5 time points, including the time of entering the operating room(Time 0),when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), 30 minutes after delivery (Time 3), and 60 minutes after delivery (Time 4).
|
30 minutes-1.5 hours
|
Pulse oxygen saturation
Time Frame: 30 minutes-1.5 hours
|
Pulse oxygen saturation will be monitored and recorded at 5 time points, including the time of entering the operating room(Time 0),when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), 30 minutes after delivery (Time 3), and 60 minutes after delivery (Time 4).
|
30 minutes-1.5 hours
|
Duration of analgesia
Time Frame: 30 minutes-1.5 hours
|
Defined as the time from labor analgesia to delivery of the fetus.
|
30 minutes-1.5 hours
|
The number of compressions
Time Frame: 30 minutes-1.5 hours
|
The number of compressions by electronic analgesia pump from labor analgesia to delivery of the fetus.
|
30 minutes-1.5 hours
|
Adverse reactions
Time Frame: 30 minutes-1.5 hours
|
The occurrence of adverse reactions(nausea, vomiting, skin itching and other adverse reactions).
|
30 minutes-1.5 hours
|
The Apgar scores
Time Frame: 30 minutes-1.5 hours
|
The Apgar scores of 1 and 5 minutes after birth will be recorded.
|
30 minutes-1.5 hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: Na Li, MD, Maternal and Child Health Hospital of Hubei Province
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Labor Pain
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Adjuvants, Anesthesia
- Anesthetics, Local
- Ropivacaine
- Sufentanil
- Hydromorphone
Other Study ID Numbers
- MCHH_002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Analgesia
-
Mansoura UniversityNot yet recruiting
-
Southeast University, ChinaRecruiting
-
Medical University of South CarolinaRecruiting
-
Southeast University, ChinaRecruiting
-
Huazhong University of Science and TechnologyRecruiting
-
Mansoura UniversityCompleted
-
University of FloridaMdoloris Medical SystemsCompletedAnalgesiaUnited States
-
Mansoura UniversityCompleted
-
Cessatech A/SCompleted
-
Kalyra Pharmaceuticals, Inc.United States Department of Defense; PRA Health SciencesTerminated
Clinical Trials on Hydromorphone
-
Mayo ClinicRecruitingPain ControlUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Brigham and Women's HospitalTerminatedPain | Healthy | PregnancyUnited States
-
Thomas Jefferson UniversityCompleted
-
Shirley Ryan AbilityLabMallinckrodtCompletedLow Back PainUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Providence Healthcare; Innerchange...CompletedHeroin Dependence | Opioid DependenceCanada
-
Fujian Cancer HospitalCompleted
-
Dr. Anthony HoRecruitingPain Control After Elective HepatectomyCanada
-
Mundipharma Research GmbH & Co KGCompletedConstipationRomania, Switzerland, Israel, Belgium, Germany, Australia, Austria, Czech Republic, Denmark, Finland, France, Netherlands, Poland, United Kingdom
-
Nova Scotia Health AuthorityCanadian Institutes of Health Research (CIHR); Nova Scotia Health Research... and other collaboratorsCompletedChronic Obstructive Pulmonary Disease (COPD)Canada